TY - JOUR
T1 - Emerging therapies in castrate-resistant prostate cancer
AU - Zarour, Luai
AU - Alumkal, Joshi
N1 - Funding Information:
Acknowledgments Dr. Joshi Alumkal’s research is supported by grants from the Flight Attendant Medical Research Institute and National Institutes of Health award number 1KL2 RR024141 01 through the Oregon Clinical and Translational Research Institute (OCTRI), grant number UL1 RR024140 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research.
PY - 2010/5
Y1 - 2010/5
N2 - Prostate cancer is the most common cancer in men in the United States, and despite screening and early treatment, more than 27,000 men are predicted to die of the disease this year, almost all of whom will die of castrate-resistant, metastatic cancers that have progressed despite androgen deprivation therapy, also known as hormonal therapy. In recent years, an increased understanding of molecular mechanisms of prostate cancer progression and castration resistance has led to improved treatment strategies. This review focuses on emerging therapies for the treatment of castrate-resistant prostate cancer, with an emphasis on the importance of the drug targets as well as the state of current clinical trials, including those utilizing hormonal therapies, biological agents, and immunotherapy that are underway or have recently been completed.
AB - Prostate cancer is the most common cancer in men in the United States, and despite screening and early treatment, more than 27,000 men are predicted to die of the disease this year, almost all of whom will die of castrate-resistant, metastatic cancers that have progressed despite androgen deprivation therapy, also known as hormonal therapy. In recent years, an increased understanding of molecular mechanisms of prostate cancer progression and castration resistance has led to improved treatment strategies. This review focuses on emerging therapies for the treatment of castrate-resistant prostate cancer, with an emphasis on the importance of the drug targets as well as the state of current clinical trials, including those utilizing hormonal therapies, biological agents, and immunotherapy that are underway or have recently been completed.
KW - Castration-resistant
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=77952233948&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952233948&partnerID=8YFLogxK
U2 - 10.1007/s11934-010-0104-x
DO - 10.1007/s11934-010-0104-x
M3 - Review article
C2 - 20425621
AN - SCOPUS:77952233948
SN - 1527-2737
VL - 11
SP - 152
EP - 158
JO - Current urology reports
JF - Current urology reports
IS - 3
ER -